These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3883733)

  • 1. Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure.
    Rudolph W; Dirschinger J
    Am Heart J; 1985 Mar; 109(3 Pt 2):670-4. PubMed ID: 3883733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-ischemic effect of 8 mg molsidomin in retard form].
    Blasini R; Brügmann U; Rudolph W
    Herz; 1984 Dec; 9(6):346-52. PubMed ID: 6392050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, randomized, placebo-controlled study of molsidomine in patients with stable effort angina receiving beta-blocker therapy with atenolol.
    De Backer GG; Derese A
    Am Heart J; 1985 Mar; 109(3 Pt 2):678-81. PubMed ID: 3883735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molsidomine in the treatment of patients with angina pectoris.
    Majid PA; DeFeyter PJ; Van der Wall EE; Wardeh R; Roos JP
    N Engl J Med; 1980 Jan; 302(1):1-6. PubMed ID: 6985697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and hemodynamic effects of the new dilator drug molsidomine.
    Malcolm AD
    Am Heart J; 1985 Mar; 109(3 Pt 2):674-7. PubMed ID: 3883734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect duration and dose-response relation of molsidomine in patients with coronary heart disease].
    Fach WA; Becker HJ
    Z Kardiol; 1984 Oct; 73(10):613-22. PubMed ID: 6393621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molsidomine in the long-term treatment of angina pectoris].
    Blasini R; Brügmann U; Mannes A; Rudolph W
    Herz; 1982 Oct; 7(5):307-16. PubMed ID: 6818116
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term clinical and hemodynamic results of molsidomine treatment in patients with refractory heart failure.
    Acar J; Kulas A; Escudier B
    Am Heart J; 1985 Mar; 109(3 Pt 2):685-7. PubMed ID: 3883737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of molsidomine on the hemodynamics of patients with chronic heart failure at rest and during exercise.
    Larbig DT; Milstrey HR; Nasse H; Kahle T
    Am Heart J; 1985 Mar; 109(3 Pt 2):688-90. PubMed ID: 3883738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ergometric study of a new vasodilator agent in angina: molsidomine. Value of combination with beta-blockaders].
    Witchitz S; Kolsky H; Moisson P; Valette H
    Arch Mal Coeur Vaiss; 1981 Apr; 74(4):463-71. PubMed ID: 6112971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention with molsidomine of coronary artery spasm caused by alkalosis.
    Weber S; Kahan A; Pailleret JJ; Guérin F; Degeorges M
    Am Heart J; 1985 Mar; 109(3 Pt 2):704-7. PubMed ID: 3838408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term molsidomine treatment versus isosorbide dinitrate and placebo on exercise tolerance in stable angina.
    Romano M; de Caprio L; Meccariello P; Cuomo S; Baldini F; D'Ascia C; Steinberg G; Chiariello M
    Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):246-9. PubMed ID: 6430811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemodynamic effects of molsidomine in patients with severe chronic coronary disease.
    Crexells C; Lidón RM; Augé JM; Bosch X; Pina C; Garcia J; Oriol A
    Eur Heart J; 1985 Dec; 6(12):1032-9. PubMed ID: 3841658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of molsidomine on left ventricular dimensions and cardiac function in patients with chronic heart failure.
    Berkenboom GM; Sobolski JC; Vandermoten PP; Stoupel EE; Degre SG
    Am Heart J; 1985 Mar; 109(3 Pt 2):691-3. PubMed ID: 3838405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic and coronary effects of molsidomine at basal state, during atrial pacing, and during cold pressor test in patients with stable angina pectoris.
    Juliard JM; Neukirch F; Zygelman M; Merillon JP; Michel PL; Pansard Y; Dahan M; Gourgon R
    Am Heart J; 1985 Mar; 109(3 Pt 2):662-6. PubMed ID: 3838404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of molsidomine at rest and during submaximal and maximal exercise in patients with coronary artery disease limited by exertional angina pectoris.
    Detry JM; Melin J; Brasseur LA; Cosyns J; Rousseau MF
    Am J Cardiol; 1981 Jan; 47(1):109-15. PubMed ID: 6893896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic effects of molsidomine in patients with heart failure following acute myocardial infarction.
    Cantelli I; Lolli C; Brunelli A; Bracchetti D
    Am Heart J; 1985 Mar; 109(3 Pt 2):716-9. PubMed ID: 3838410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of molsidomine on exercise tolerance in patients with exertional angina pectoris.
    Kinoshita M; Sawamura M; Motomura M; Takayama Y; Kawaguchi Y; Kawakita S
    Jpn Circ J; 1983 Dec; 47(12):1398-405. PubMed ID: 6689183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of molsidomine on global and regional left ventricular function at rest and during exercise in patients with angina pectoris.
    Nechwatal W; Stauch M; Sigel H; Kress P; Bitter F; Geffers H; Adam WE
    Clin Cardiol; 1981; 4(5):248-53. PubMed ID: 6895491
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the chronic antianginal effect of molsidomine.
    Dalla-Volta S; Scorzelli L; Razzolini R
    Am Heart J; 1985 Mar; 109(3 Pt 2):682-4. PubMed ID: 3883736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.